Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background/Aims: Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown. Methods: A total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed. Results: During a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1–9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5–10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years. Conclusions: The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.
Abstract
Background/Aims: Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown. Methods: A total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed. Results: During a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1–9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5–10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years. Conclusions: The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.
참고문헌 (50)
- Forner A, "Hepatocellular carcinoma", Lancet, 379, pp.1245~1255 (2012)
- Sayiner M, "Disease burden of hepatocellular carcinoma : a global perspective", Dig Dis Sci, 64, pp.910~917 (2019)
- Roayaie S, "A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma", Gastroenterology, 137, pp.850~855 (2009)
- Shen YC, "Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma(HCC) : a meta-regression approach", J Hepatol, 52, pp.889~894 (2010)
- Belghiti J, "Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis", Ann Surg, 214, pp.114~117 (1991)
- Kumada T, "Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma", Hepatology, 25, pp.87~92 (1997)
- Montorsi M, "Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients : a multivariate analysis", J Gastrointest Surg, 9, pp.62~67 (2005)
- Rhim H, "Radiofrequency ablation of hepatocellular carcinoma : pros and cons", Gut Liver, 4(Suppl 1), pp.S113~S118 (2010)
- Baiocchi GL, "Follow-up after gastrectomy for cancer : the Charter Scaligero Consensus Conference", Gastric Cancer, 19, pp.15~20 (2016)
- Aurello P, "Follow-up after curative resection for gastric cancer : is it time to tailor it?", World J Gastroenterol, 23, pp.3379~3387 (2017)
- Fahy BN, "Follow-up after curative resection of colorectal cancer", Ann Surg Oncol, 21, pp.738~746 (2014)
- "Clinical Practice Guidelines in Oncology (NCCN Guidelines) — Gastric Cancer. Version 2.2019" (2019)[URL]
- "Clinical Practice Guidelines in Oncology (NCCN Guidelines) — Colon Cancer. Version 2.2019" (2019)[URL]
- Tung-Ping Poon R, "Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma", Ann Surg, 232, pp.10~24 (2000)
- 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
- 김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회
- Park JW, "Practice guideline for diagnosis and treatment of hepatocellular carcinoma", Korean J Hepatol, 10, pp.88~98 (2004)
- 장재영, "The General Rules for the Study of Primary Liver Cancer", Journal of Liver Cancer, 17(1), pp.19~44 (2017), 대한간암학회
- Johnson PJ, "Assessment of liver function in patients with hepatocellular carcinoma : a new evidence-based approach-the ALBI grade", J Clin Oncol, 33, pp.550~558 (2015)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- "Important policy notice:clerical changes for implementation of adding serum sodium to the MELD Score"[URL]
- Hanyu T, "Carcinoma in the remnant stomach during long-term follow-up after distal gastrectomy for gastric cancer : analysis of cumulative incidence and associated risk factors", World J Surg, 42, pp.782~787 (2018)
- "Stomach. Source: Globocan 2018"[URL]
- Cao L, "Risk factors for recurrence in T1-2N0 gastric cancer in the United States and China", J Surg Oncol, 113, pp.745~749 (2016)
- Nilsson M, "Postgastrectomy follow-up in the West : evidence base, guidelines, and daily practice", Gastric Cancer, 20(Suppl 1), pp.135~140 (2017)
- Bouvier AM, "Incidence and patterns of late recurrences in colon cancer patients", Int J Cancer, 137, pp.2133~2138 (2015)
- "Colorectal cancer. Source: Globocan 2018"[URL]
- Kahi CJ, "Colonoscopy surveillance after colorectal cancer resection : recommendations of the US Multi-Society Task Force on colorectal cancer", Gastroenterology, 150, pp.758~768.e11 (2016)
- Rusiecki J, "Colonoscopy surveillance after colorectal cancer resection", JAMA, 318, pp.2346~2347 (2017)
- Zheng J, "Actual 10-year survivors after resection of hepatocellular carcinoma", Ann Surg Oncol, 24, pp.1358~1366 (2017)
- Shiina S, "Radiofrequency ablation for hepatocellular carcinoma : 10-year outcome and prognostic factors", Am J Gastroenterol, 107, pp.569~577 (2012)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- 조주연, "Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma", Clinical and Molecular Hepatology, 22(4), pp.477~486 (2016), 대한간학회[DOI]
- Hirokawa F, "Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma", Surg Oncol, 25, pp.24~29 (2016)
- Imamura H, "Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy", J Hepatol, 38, pp.200~207 (2003)
- Jong Man Kim, "Early disseminated recurrence after liver resection in solitary hepatocellular carcinoma", Annals of Surgical Treatment and Research, 94(3), pp.129~134 (2018), 대한외과학회
- Poon RT, "Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma", Cancer, 89, pp.500~507 (2000)
- Xu XF, "Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma : a multicenter study from China", JAMA Surg, 154, pp.209~217 (2019)
- Yamamoto Y, "Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy", World J Gastroenterol, 21, pp.1207~1215 (2015)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
- Kim BK, "Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients", Liver Int, 30, pp.546~553 (2010)
- Zhang Y, "FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: a metaanalysis", 97, pp.e13696~ (2018)
- Santi V, "Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival", J Hepatol, 53, pp.291~297 (2010)
- Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a meta-analysis", Gastroenterology, 154, pp.1706~1718.e1 (2018)
- Fattovich G, "Hepatocellular carcinoma in cirrhosis : incidence and risk factors", Gastroenterology, 127(5 Suppl 1), pp.S35~S50 (2004)
- Papatheodoridis GV, "The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B", Hepatology, 66, pp.1444~1453 (2017)
- Kim BG, "The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B", Liver Int, 38, pp.2269~2276 (2018)
- 김정희, "Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma", Gut and Liver, 10(6), pp.939~947 (2016), 거트앤리버 소화기연관학회협의회